Both cRLN2 and cRLN2-CO treatments significantly decreased AST and ALT levels (Figure 6B) and liver echogenicity (Figure 6C), indicating a reversal of liver fibrosis. The gene discussed is GPT; the disease is Hepatic fibrosis.